Volume 93, Issue 5 pp. 523-531
Free to Read

High Expression of Human Uroplakin Ia in Urinary Bladder Transitional Cell Carcinoma

Susumu Kageyama

Susumu Kageyama

Department of Urology, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192

Search for more papers by this author
Tatsuhiro Yoshiki

Corresponding Author

Tatsuhiro Yoshiki

Department of Urology, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192

To whom correspondence should be addressed. E-mail: [email protected]Search for more papers by this author
Takahiro Isono

Takahiro Isono

Central Research Laboratory, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192

Search for more papers by this author
Tsutomu Tanaka

Tsutomu Tanaka

Department of Urology, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192

Search for more papers by this author
Choi Jang Kim

Choi Jang Kim

Department of Urology, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192

Search for more papers by this author
Takeshi Yuasa

Takeshi Yuasa

Department of Urology, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192

Search for more papers by this author
Yusaku Okada

Yusaku Okada

Department of Urology, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192

Search for more papers by this author
First published: 30 August 2005
Citations: 23

http://www.ncc.go.jp/jp/statistics/1999/index_i.html (The last date of access was November 1st 2001.) Cancer Statistics in Japan 1999. The Foundation for Promotion of Cancer Research.

Abstract

Uroplakins (UPs) Ia, Ib, II, and III are tissue-specific and differentiation-dependent transmem-brane proteins of the urothelium. We assessed the usefulness of human UP Ia as a histological marker by examining its expression in urinary bladder transitional cell carcinoma (TCC). A polyclonal antibody against human UP Ia was raised using a synthesized polypeptide. We applied our antibody to various organ tissues, including urothelium, and observed no crossreactivity. Analysis by RT-PCR of normal urothelium, TCC and other organ tissues indicated that the human UP Ia gene expression is highly specialized to urothelium, and is conserved in TCC. Using immunohistochemistry, we investigated the expression of UP Ia in TCC from patients who had undergone radical cystectomy and from autopsy cases. Positive staining (10% or more positive cancer cells) was noted in primary lesions from 61 of 63 (96.8%) cystectomy patients. Depending on pathological grade, high expression (50% or more positive cancer cells) was observed in 17 of 18 (94.4%) moderately- to well-differentiated TCC and in 36 of 45 (80.0%) poorly differentiated TCC. With regard to tumor invasion, high expression was noted in 20 of 22 (90.9%) superficial and 33 of 41 (80.5%) muscle-invasive TCC. Cause-specific survival rates were 68.6% and 75.0% in high- and low-expression patients, respectively (log-rank test, P=0.855, mean follow-up; 65.0 months). In metastases, positive reactions were observed in 13 of 18 (72.2%) lesions. UP Ia may represent a specific histological marker judging from the stable expression, although its value as a prognostic factor remains undetermined.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.